BCRX BioCryst Pharmaceuticals Inc

$6.97

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

BioCryst Pharmaceuticals, with a market cap of approximately $1.46 billion, is poised for its upcoming earnings release on November 3, 2025, amid a backdrop of investor anticipation and strategic growth potential. The company, known for its innovative treatments, is expected to report an EPS of $0.05, with revenue projections reaching $162.97 million. Notably, the whisper number suggests a slightly higher EPS of $0.06, indicating a cautious optimism among investors who are closely watching BioCryst's ability to capitalize on its pipeline advancements. While recent news has been sparse, the focus remains on how BioCryst leverages its existing portfolio and new developments to drive financial performance. As the market awaits these results, the company's strategic direction and execution will be key in meeting or exceeding these expectations, potentially influencing its market valuation and investor sentiment.

Updated On 11/21/2025

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.

Website: https://www.biocryst.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
882796
Address
4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US
Valuation
Market Cap
$1.55B
P/E Ratio
nan
PEG Ratio
-0.28
Price to Book
56.59
Performance
EPS
$-0.43
Dividend Yield
—
Profit Margin
-19.70%
ROE
-1925.00%
Technicals
50D MA
$7.93
200D MA
$7.70
52W High
$9.50
52W Low
$4.03
Fundamentals
Shares Outstanding
209M
Target Price
$14.73
Beta
1.75

BCRX EPS Estimates vs Actual

● Estimated
● Actual

BCRX News & Sentiment

Nov 21, 2025 • Motley Fool SOMEWHAT-BULLISH
Why Dyne Therapeutics Stock Was Crushing it This Week
The company has solid potential with its development of drugs targeting muscle disorders.
Nov 05, 2025 • GlobeNewswire SOMEWHAT-BULLISH
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 30,700 ...
Nov 05, 2025 • Benzinga SOMEWHAT-BULLISH
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 30,700 ...
Nov 03, 2025 • Motley Fool SOMEWHAT-BULLISH
BioCryst ( BCRX ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, Nov. 3, 2025 at 8:30 a.m. ETChief Executive Officer - John StonehouseContinue reading ...
Nov 03, 2025 • Benzinga NEUTRAL
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies ( NASDAQ:PLTR )
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. Here's a look at the names most likely to be on individual investors' radars. CIFR stock is soaring. Watch the real-time price action here.
Oct 30, 2025 • Zacks Commentary NEUTRAL
Ardelyx ( ARDX ) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.230
50 articles with scored sentiment

Overall Sentiment:

Bullish

BCRX Reported Earnings

Aug 04, 2025
Jun 30, 2025 (Pre market)
0.14 Surprise
  • Reported EPS: $0.15
  • Estimate: $0.01
  • Whisper: —
  • Surprise %: 1400.0%
May 05, 2025
Mar 31, 2025 (Pre market)
0.21 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.21
  • Whisper: —
  • Surprise %: 100.0%
Feb 24, 2025
Dec 31, 2024 (Pre market)
-0.07 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -115.2%
Nov 04, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.07
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -16.7%
Aug 05, 2024
Jun 30, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.06
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: 64.7%
May 06, 2024
Mar 31, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.17
  • Estimate: $-0.21
  • Whisper: —
  • Surprise %: 19.1%
Feb 26, 2024
Dec 31, 2023 (Pre market)
-0.04 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: -16.7%
Nov 02, 2023
Sep 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.23
  • Whisper: —
  • Surprise %: 17.4%
Aug 03, 2023
Jun 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.24
  • Estimate: $-0.23
  • Whisper: —
  • Surprise %: -4.3%

Financials